Several studies have indicated that home infusions of biologic agents are safe for selected patients with inflammatory bowel disease. Vedolizumab is a monoclonal antibody directed against the α4β7 integrin and is indicated for the treatment of moderate to severe ulcerative colitis (UC) and Crohn’s disease (CD) in patients that have had an inadequate response to or demonstrated intolerability to corticosteroids, immunomodulators, or TNF-α inhibitors. Its novel GI-selective target suggests that associated adverse events may differ than those in older biologics.